ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Clinical trials for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE explained in plain language.
Never miss a new study
Get alerted when new ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE trials appear
Sign up with your email to follow new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Supercharged donor cells take on stubborn lymphomas
Disease control Recruiting nowThis early-stage study tests a new type of cell therapy for people with certain lymphomas that have come back or not responded to treatment. The therapy uses immune cells from healthy donors that are modified to better recognize and attack cancer cells, plus an added molecule to …
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated May 17, 2026 02:59 UTC
-
New pill may help prevent lymphoma relapse after chemo
Disease control Recruiting nowThis study tests whether the drug golidocitinib can help keep peripheral T-cell lymphoma (a type of blood cancer) from returning in patients who have already responded to initial chemotherapy. About 136 adults who are not eligible for or decline a stem cell transplant will receiv…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could a stem cell transplant keep T-Cell lymphoma away longer?
Disease control Recruiting nowThis study compares two approaches for people with peripheral T-cell lymphoma who are in complete remission after initial treatment: either high-dose chemotherapy followed by a transplant of their own stem cells, or simply watching and waiting. The goal is to see if the transplan…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated May 14, 2026 12:06 UTC